Zhe Dai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhe Dai has a total of 394 co-authors. Here are the top co-authors by number of shared publications:
Jun Tang
Zhongnan Hospital of Wuhan University
18 shared publicationsHuawei Wang
Zhongnan Hospital of Wuhan University
15 shared publications- Yancheng Xu
Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
14 shared publications Yonge Wang
Zhongnan Hospital of Wuhan University
9 shared publicationsFang Liu
Zhongnan Hospital of Wuhan University
8 shared publicationsJiawei Chen
Zhongnan Hospital of Wuhan University
8 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0343078
Efficacy, safety, and feasibility of youth-derived fecal microbiota transplantation among adults with type 1 diabetes mellitus: A protocol of Pilot Randomized Controlled Trial
Background: Dysbiosis of gut microbiota plays a key role in type 1 diabetes mellitus (T1DM). Fecal microbiota transplantation represents a novel therapeutic avenue. We hypothesize that youth-derived fecal microbiota transplantation (yFMT) can remodel the gut microecosystem and improve clinical outcomes. This pilot trial aims to assess the feasibility, safety, and preliminary efficacy of yFMT in adults with T1DM. Methods and analysis: This single-center, randomized, double-blind, placebo-controlled pilot study will enroll adults with T1DM who have suboptimal glycemic outcomes (glycated hemoglobin [HbA1c] of 7.0–14.0% or time in range [TIR] 70% and time below range <4% at 12 weeks post-randomization. Secondary efficacy endpoints include: (1) the change from baseline in the same composite achievement rate at 4 weeks post-intervention; (2) changes from baseline at Weeks 4 and 12 in other glycemic metrics (including HbA1c, fasting plasma glucose, 2-hour postprandial glucose, and additional CGM metrics), C-peptide, immune responses, infection markers, and gut microbiota composition; and (3) changes from baseline at Week 12 in serum metabolomic profiles (bile acids, short-chain fatty acids, and other related metabolites). Feasibility will be assessed through recruitment rate, retention rate, intervention adherence, and acceptability. Safety endpoints include the incidence of adverse events and serious adverse events. Discussion: Our findings will offer new insight into the feasibility and effects of oral yFMT capsules in adults with T1DM and provide the necessary evidence to power a subsequent multicenter large-scale study. Exploratory biomarker analyses conducted within this study may further pave the way for future individualized microbiome‑based therapeutics. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR2500111955 (November 7, 2025).
- 21 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0343078
Open AccessEfficacy, safety, and feasibility of youth-derived fecal microbiota transplantation among adults with type 1 diabetes mellitus: A protocol of Pilot Randomized Controlled Trial
Background: Dysbiosis of gut microbiota plays a key role in type 1 diabetes mellitus (T1DM). Fecal microbiota transplantation represents a novel therapeutic avenue. We hypothesize that youth-derived fecal microbiota transplantation (yFMT) can remodel the gut microecosystem and improve clinical outcomes. This pilot trial aims to assess the feasibility, safety, and preliminary efficacy of yFMT in adults with T1DM. Methods and analysis: This single-center, randomized, double-blind, placebo-controlled pilot study will enroll adults with T1DM who have suboptimal glycemic outcomes (glycated hemoglobin [HbA1c] of 7.0–14.0% or time in range [TIR] 70% and time below range <4% at 12 weeks post-randomization. Secondary efficacy endpoints include: (1) the change from baseline in the same composite achievement rate at 4 weeks post-intervention; (2) changes from baseline at Weeks 4 and 12 in other glycemic metrics (including HbA1c, fasting plasma glucose, 2-hour postprandial glucose, and additional CGM metrics), C-peptide, immune responses, infection markers, and gut microbiota composition; and (3) changes from baseline at Week 12 in serum metabolomic profiles (bile acids, short-chain fatty acids, and other related metabolites). Feasibility will be assessed through recruitment rate, retention rate, intervention adherence, and acceptability. Safety endpoints include the incidence of adverse events and serious adverse events. Discussion: Our findings will offer new insight into the feasibility and effects of oral yFMT capsules in adults with T1DM and provide the necessary evidence to power a subsequent multicenter large-scale study. Exploratory biomarker analyses conducted within this study may further pave the way for future individualized microbiome‑based therapeutics. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR2500111955 (November 7, 2025).
- Open Access
- 13 July 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1893666
Case Report: Recurrent abdominal pain with elevated pancreatic enzymes in type 2 diabetes mellitus: a case of IgG4-related autoimmune pancreatitis misdiagnosed as acute pancreatitis
Background: IgG4-related autoimmune pancreatitis (IgG4-AIP) is a rare autoimmune pancreatic disorder with non-specific clinical manifestations that is often misdiagnosed as acute pancreatitis (AP). Its coexistence with type 2 diabetes mellitus (T2DM) may further complicate recognition of the underlying pancreatic disease. Case presentation: A 60-year-old male with a 4-year history of T2DM was admitted for diabetic complications manifesting as blurred vision and lower limb numbness. During hospitalization, he developed recurrent epigastric pain associated with elevated pancreatic enzymes and was initially diagnosed with AP. Conventional treatment for AP did not lead to sustained improvement, and amylase and lipase remained persistently elevated. Serum IgG4 was markedly elevated at 13.8 g/L. Imaging findings were unremarkable. Endoscopic ultrasound-guided fine-needle aspiration revealed chronic inflammatory changes. The diagnosis of IgG4-AIP was ultimately established based on the markedly elevated serum IgG4 level, supportive (though atypical) imaging findings, histopathological features, and a favorable response to glucocorticoid therapy. The patient’s symptoms improved, accompanied by an overall decrease in serum IgG4 and pancreatic enzyme levels. Conclusion: In T2DM patients with recurrent abdominal pain and persistently elevated pancreatic enzymes unresponsive to routine AP treatment, IgG4-AIP should be considered. Timely measurement of serum IgG4 and careful integration of imaging, histopathology, and treatment response are important for early diagnosis. Early recognition may prevent misdiagnosis and enable timely initiation of glucocorticoid therapy.
- 13 July 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1893666
Open AccessCase Report: Recurrent abdominal pain with elevated pancreatic enzymes in type 2 diabetes mellitus: a case of IgG4-related autoimmune pancreatitis misdiagnosed as acute pancreatitis
Background: IgG4-related autoimmune pancreatitis (IgG4-AIP) is a rare autoimmune pancreatic disorder with non-specific clinical manifestations that is often misdiagnosed as acute pancreatitis (AP). Its coexistence with type 2 diabetes mellitus (T2DM) may further complicate recognition of the underlying pancreatic disease. Case presentation: A 60-year-old male with a 4-year history of T2DM was admitted for diabetic complications manifesting as blurred vision and lower limb numbness. During hospitalization, he developed recurrent epigastric pain associated with elevated pancreatic enzymes and was initially diagnosed with AP. Conventional treatment for AP did not lead to sustained improvement, and amylase and lipase remained persistently elevated. Serum IgG4 was markedly elevated at 13.8 g/L. Imaging findings were unremarkable. Endoscopic ultrasound-guided fine-needle aspiration revealed chronic inflammatory changes. The diagnosis of IgG4-AIP was ultimately established based on the markedly elevated serum IgG4 level, supportive (though atypical) imaging findings, histopathological features, and a favorable response to glucocorticoid therapy. The patient’s symptoms improved, accompanied by an overall decrease in serum IgG4 and pancreatic enzyme levels. Conclusion: In T2DM patients with recurrent abdominal pain and persistently elevated pancreatic enzymes unresponsive to routine AP treatment, IgG4-AIP should be considered. Timely measurement of serum IgG4 and careful integration of imaging, histopathology, and treatment response are important for early diagnosis. Early recognition may prevent misdiagnosis and enable timely initiation of glucocorticoid therapy.
- 6 July 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (9) , 8637-8648
Efficacy and Safety of Tubeless Hybrid Closed‐Loop Systems in Type 1 Diabetes: A Meta‐Analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy and safety of tubeless hybrid closed‐loop (HCL) systems in type 1 diabetes (T1D). Methods: We searched Web of Science, PubMed, Scopus, and Embase from inception to April 1 st , 2026 for randomized controlled trials (RCTs) comparing tubeless HCL systems with standard care (SC; sensor‐augmented pumps [SAP] or multiple daily injections [MDI] + continuous glucose monitoring [CGM]). Primary efficacy outcomes were time in range of 3.9–10.0 mmol/L (TIR) and glycated haemoglobin (HbA1c). Secondary efficacy outcomes included time above range (TAR10.0, TAR13.9), time below range (TBR3.9, TBR3.0), and coefficient of variability (CV). Safety outcomes included severe hypoglycaemia (SH) and diabetic ketoacidosis (DKA) risks. Random‐ or fixed‐effects models were used as appropriate. Results: Four RCTs involving 514 participants were included. The mean age was 32.3 ± 15.7 years, with a mean T1D duration of 14.7 ± 11.1 years, and with mean baseline HbA1c 8.0% ± 1.0%. Three studies compared tubeless HCL with SAP, and one with MDI + CGM. Compared with SC, tubeless HCL improved TIR (MD = 15.31%, 95% CI [7.67%, 22.95%], I 2 = 95%, p < 0.001) and HbA1c (MD = −0.46%, 95% CI [−0.79%, −0.14%], I 2 = 91%, p = 0.005). Lower levels of TAR (TAR10.0, TAR13.9), TBR3.9 and CV were also observed (all p < 0.001) in tubeless HCL group. No significant differences were observed in TBR3.0 (MD = −0.06%, 95% CI [−0.17%, 0.06%], I 2 = 71%, p = 0.35) and insulin dose. DKA and SH events were rare in both groups. Conclusions: The available evidence suggests that tubeless HCL systems may improve glycaemic control without increasing insulin dose or short‐term safety risks. Head‐to‐head trials using identical algorithms are needed to isolate form‐factor‐specific effects.
- 6 July 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (9) , 8637-8648
Efficacy and Safety of Tubeless Hybrid Closed‐Loop Systems in Type 1 Diabetes: A Meta‐Analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy and safety of tubeless hybrid closed‐loop (HCL) systems in type 1 diabetes (T1D). Methods: We searched Web of Science, PubMed, Scopus, and Embase from inception to April 1 st , 2026 for randomized controlled trials (RCTs) comparing tubeless HCL systems with standard care (SC; sensor‐augmented pumps [SAP] or multiple daily injections [MDI] + continuous glucose monitoring [CGM]). Primary efficacy outcomes were time in range of 3.9–10.0 mmol/L (TIR) and glycated haemoglobin (HbA1c). Secondary efficacy outcomes included time above range (TAR10.0, TAR13.9), time below range (TBR3.9, TBR3.0), and coefficient of variability (CV). Safety outcomes included severe hypoglycaemia (SH) and diabetic ketoacidosis (DKA) risks. Random‐ or fixed‐effects models were used as appropriate. Results: Four RCTs involving 514 participants were included. The mean age was 32.3 ± 15.7 years, with a mean T1D duration of 14.7 ± 11.1 years, and with mean baseline HbA1c 8.0% ± 1.0%. Three studies compared tubeless HCL with SAP, and one with MDI + CGM. Compared with SC, tubeless HCL improved TIR (MD = 15.31%, 95% CI [7.67%, 22.95%], I 2 = 95%, p < 0.001) and HbA1c (MD = −0.46%, 95% CI [−0.79%, −0.14%], I 2 = 91%, p = 0.005). Lower levels of TAR (TAR10.0, TAR13.9), TBR3.9 and CV were also observed (all p < 0.001) in tubeless HCL group. No significant differences were observed in TBR3.0 (MD = −0.06%, 95% CI [−0.17%, 0.06%], I 2 = 71%, p = 0.35) and insulin dose. DKA and SH events were rare in both groups. Conclusions: The available evidence suggests that tubeless HCL systems may improve glycaemic control without increasing insulin dose or short‐term safety risks. Head‐to‐head trials using identical algorithms are needed to isolate form‐factor‐specific effects.
- Open Access
- 10 June 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1820368
Reduced activity of two LPL C-terminal variants, p.Glu396Val and novel p.Trp417Cys: a clinical, biochemical and structural study
Background: Lipoprotein lipase (LPL) is essential for plasma triglyceride (TG) hydrolysis, and biallelic LPL loss-of-function variants cause familial chylomicronemia syndrome. However, the clinical and functional significance of heterozygous LPL variants remains incompletely characterized. We investigated two heterozygous LPL missense variants, c.1187A>T (p.Glu396Val) and the novel c.1251G>C (p.Trp417Cys), in patients with severe hypertriglyceridemia (HTG). Methods: Two probands underwent comprehensive clinical, biochemical, and imaging assessments. Genetic analysis involved whole-exome sequencing and Sanger confirmation. Variant interpretation incorporated in silico prediction, evolutionary conservation, AlphaFold-based residue mapping, LPL-GPIHBP1 structural-context analysis, and NetCGlyc prediction. Functional effects were assessed in HEK293T cells transfected with wild-type or mutant LPL plasmids, measuring mRNA/protein expression and enzymatic activity. Results: Clinically, Proband 1 exhibited recurrent pancreatitis with moderate hyperglycemia, whereas Proband 2 had extreme HTG without pancreatitis but with severe insulin resistance, reflecting variable expressivity. Two LPL missense variants, c.1187A>T (p.Glu396Val) and the novel c.1251G>C (p.Trp417Cys), both located in exon 8. Both affected residues were highly conserved and localized to the C-terminal domain by AlphaFold-based mapping. NetCGlyc predicted Trp417 as a potential C-mannosylation-related residue. Mutant LPL mRNA and protein expression were comparable to wild-type, whereas enzymatic activity was significantly reduced in cell lysates and culture medium. Conclusions: These findings provide functional evidence that p.Glu396Val and the novel p.Trp417Cys impair LPL enzymatic activity despite preserved protein abundance, supporting a qualitative functional defect. Our findings highlight the value of functional validation and metabolic assessment in interpreting heterozygous LPL variants in HTG.
- 10 June 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1820368
Open AccessReduced activity of two LPL C-terminal variants, p.Glu396Val and novel p.Trp417Cys: a clinical, biochemical and structural study
Background: Lipoprotein lipase (LPL) is essential for plasma triglyceride (TG) hydrolysis, and biallelic LPL loss-of-function variants cause familial chylomicronemia syndrome. However, the clinical and functional significance of heterozygous LPL variants remains incompletely characterized. We investigated two heterozygous LPL missense variants, c.1187A>T (p.Glu396Val) and the novel c.1251G>C (p.Trp417Cys), in patients with severe hypertriglyceridemia (HTG). Methods: Two probands underwent comprehensive clinical, biochemical, and imaging assessments. Genetic analysis involved whole-exome sequencing and Sanger confirmation. Variant interpretation incorporated in silico prediction, evolutionary conservation, AlphaFold-based residue mapping, LPL-GPIHBP1 structural-context analysis, and NetCGlyc prediction. Functional effects were assessed in HEK293T cells transfected with wild-type or mutant LPL plasmids, measuring mRNA/protein expression and enzymatic activity. Results: Clinically, Proband 1 exhibited recurrent pancreatitis with moderate hyperglycemia, whereas Proband 2 had extreme HTG without pancreatitis but with severe insulin resistance, reflecting variable expressivity. Two LPL missense variants, c.1187A>T (p.Glu396Val) and the novel c.1251G>C (p.Trp417Cys), both located in exon 8. Both affected residues were highly conserved and localized to the C-terminal domain by AlphaFold-based mapping. NetCGlyc predicted Trp417 as a potential C-mannosylation-related residue. Mutant LPL mRNA and protein expression were comparable to wild-type, whereas enzymatic activity was significantly reduced in cell lysates and culture medium. Conclusions: These findings provide functional evidence that p.Glu396Val and the novel p.Trp417Cys impair LPL enzymatic activity despite preserved protein abundance, supporting a qualitative functional defect. Our findings highlight the value of functional validation and metabolic assessment in interpreting heterozygous LPL variants in HTG.
- Open Access
- 25 February 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1705021
Gut microbiota in obesity management: from microbial clocks to precision microbial therapies
The gut microbiota exhibits robust circadian oscillations that synchronize with host metabolic cycles. Disruption of these microbial rhythms is increasingly recognized as a factor contributing to the pathogenesis of obesity. Clinical evidence supports that chrono-modulated interventions, including chrono-nutrition, temporal fecal microbiota transplantation (FMT), and engineered microbial systems, represent promising approaches in obesity management. This review synthesizes the features of gut microbiota circadian dynamics, the intrinsic and extrinsic factors regulating microbiota oscillations, and the precise microbial intervention measures targeting temporal patterns. Through the integration of insights into the microbiota-clock-metabolism axis, this review emphasizes the necessity of time-specific strategies in translating microbial circadian biology into effective, personalized obesity therapies.
- 25 February 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1705021
Open AccessGut microbiota in obesity management: from microbial clocks to precision microbial therapies
The gut microbiota exhibits robust circadian oscillations that synchronize with host metabolic cycles. Disruption of these microbial rhythms is increasingly recognized as a factor contributing to the pathogenesis of obesity. Clinical evidence supports that chrono-modulated interventions, including chrono-nutrition, temporal fecal microbiota transplantation (FMT), and engineered microbial systems, represent promising approaches in obesity management. This review synthesizes the features of gut microbiota circadian dynamics, the intrinsic and extrinsic factors regulating microbiota oscillations, and the precise microbial intervention measures targeting temporal patterns. Through the integration of insights into the microbiota-clock-metabolism axis, this review emphasizes the necessity of time-specific strategies in translating microbial circadian biology into effective, personalized obesity therapies.
- Open Access
Efficacy and safety of Youth-derived Fecal Microbiota Transplantation among adults with Type 1 Diabetes Mellitus: A protocol of pilot randomized controlled trial
Background: Dysbiosis of gut microbiota plays a key role in type 1 diabetes mellitus (T1DM). Fecal microbiota transplantation represents a novel therapeutic avenue. We hypothesize that youth-derived fecal microbiota transplantation (yFMT) can remodel the gut microecosystem and improve clinical outcomes. This study aims to investigate the efficacy and safety of orally administered yFMT capsules in adults with T1DM. Methods and analysis: This single-center, randomized, double-blind, placebo-controlled pilot study will enroll adults with T1DM who have suboptimal glycemic outcomes (glycated hemoglobin[HbA1c] of 7-14% and time in range [TIR] 70% and time below range<4% at 4 and 12 weeks post-randomization. Secondary efficacy endpoints comprise changes from baseline at weeks 4 and 12 in other glycemic metrics (including HbA1c, fasting glucose, 2-hour postprandial glucose, and additional CGM metrics), C-peptide, immune responses, infection markers, and gut microbiota composition. Changes from baseline at week 12 in serum metabolomic profiles will also be assessed, encompassing bile acids, short-chain fatty acids, and other related metabolites. Safety endpoints include the incidence of adverse events and serious adverse events. Discussion: Our findings will offer new insight into the feasibility and effects of oral yFMT in adult with T1DM and provide the necessary evidence to power a subsequent multicenter large-scale study. Exploratory biomarker analyses conducted within this study may further pave the way for future individualized microbiome–based therapeutics. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR2500111955 (November 7, 2025).
Open AccessEfficacy and safety of Youth-derived Fecal Microbiota Transplantation among adults with Type 1 Diabetes Mellitus: A protocol of pilot randomized controlled trial
Background: Dysbiosis of gut microbiota plays a key role in type 1 diabetes mellitus (T1DM). Fecal microbiota transplantation represents a novel therapeutic avenue. We hypothesize that youth-derived fecal microbiota transplantation (yFMT) can remodel the gut microecosystem and improve clinical outcomes. This study aims to investigate the efficacy and safety of orally administered yFMT capsules in adults with T1DM. Methods and analysis: This single-center, randomized, double-blind, placebo-controlled pilot study will enroll adults with T1DM who have suboptimal glycemic outcomes (glycated hemoglobin[HbA1c] of 7-14% and time in range [TIR] 70% and time below range<4% at 4 and 12 weeks post-randomization. Secondary efficacy endpoints comprise changes from baseline at weeks 4 and 12 in other glycemic metrics (including HbA1c, fasting glucose, 2-hour postprandial glucose, and additional CGM metrics), C-peptide, immune responses, infection markers, and gut microbiota composition. Changes from baseline at week 12 in serum metabolomic profiles will also be assessed, encompassing bile acids, short-chain fatty acids, and other related metabolites. Safety endpoints include the incidence of adverse events and serious adverse events. Discussion: Our findings will offer new insight into the feasibility and effects of oral yFMT in adult with T1DM and provide the necessary evidence to power a subsequent multicenter large-scale study. Exploratory biomarker analyses conducted within this study may further pave the way for future individualized microbiome–based therapeutics. Trial registration: Chinese Clinical Trial Registry identifier: ChiCTR2500111955 (November 7, 2025).
- Open Access
- 16 January 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1734612
Gut microbiota signatures across BMI categories in adults and combined diagnostic value with clinical indicators for early obesity risk stratification
Background: The global prevalence of obesity continues to rise, with gut microbiota implicated as a key environmental factor in its development. However, microbial heterogeneity across BMI categories and its potential as an early diagnostic marker remain poorly understood. Here, we systematically compared the gut microbiota of adults with normal weight, overweight, and obesity, and evaluated the diagnostic utility of integrated microbial and clinical indicators. Methods: In this study, a cohort of 214 participants was recruited and categorized into three groups based on BMI: normal weight (Nor, n = 85), overweight (Ow, n = 91), and obesity (Ob, n = 38). The gut microbiota was analyzed using 16S rRNA sequencing, which facilitated the assessment of α - and β -diversity, the identification of differentially abundant bacterial genera, and the evaluation of Spearman correlations with clinical indicators. Additionally, a diagnostic model was developed utilizing random forest, Least Absolute Shrinkage and Selection Operator (LASSO) regression and receiver operating characteristic (ROC) curve analysis. Results: Clinical data showed no significant age differences among groups ( p > 0.05), but the Ob group had markedly higher weight, BMI, total cholesterol, triglycerides, and uric acid levels ( p < 0.001). Microbial analysis revealed reduced alpha diversity (Shannon index) in the Ob group and distinct microbial community structures among groups (PCoA, p < 0.001). LEfSe analysis showed enrichment of Escherichia-Shigella , Lactobacillus , and Parabacteroides in the Ob group, while Faecalibacterium , Enterobacter , and Agathobacter were predominant in the Nor group. The Ow group exhibited intermediate or specific enrichment, particularly in Ruminococcus gnavus group , Morganella , and Clostridium innocuum group . Correlation analysis indicated that bacteria abundant in the Nor group negatively correlated with BMI, TG, LDL-C, and positively with HDL-C, whereas those enriched in the Ow and Ob groups showed opposite trends. Four genera differentiated Ob from Ow individuals (AUC = 0.684), eight distinguished Ob from Nor (AUC = 0.787), and five separated Ow from Nor (AUC = 0.721). Integrating microbial and clinical data notably improved classification, with AUCs increasing to 0.908, 0.969, and 0.995, respectively. Conclusion: Intestinal microecological profiles vary significantly across BMI categories, and a model combining microbiota with metabolic markers shows strong potential for early obesity detection.
- 16 January 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1734612
Open AccessGut microbiota signatures across BMI categories in adults and combined diagnostic value with clinical indicators for early obesity risk stratification
Background: The global prevalence of obesity continues to rise, with gut microbiota implicated as a key environmental factor in its development. However, microbial heterogeneity across BMI categories and its potential as an early diagnostic marker remain poorly understood. Here, we systematically compared the gut microbiota of adults with normal weight, overweight, and obesity, and evaluated the diagnostic utility of integrated microbial and clinical indicators. Methods: In this study, a cohort of 214 participants was recruited and categorized into three groups based on BMI: normal weight (Nor, n = 85), overweight (Ow, n = 91), and obesity (Ob, n = 38). The gut microbiota was analyzed using 16S rRNA sequencing, which facilitated the assessment of α - and β -diversity, the identification of differentially abundant bacterial genera, and the evaluation of Spearman correlations with clinical indicators. Additionally, a diagnostic model was developed utilizing random forest, Least Absolute Shrinkage and Selection Operator (LASSO) regression and receiver operating characteristic (ROC) curve analysis. Results: Clinical data showed no significant age differences among groups ( p > 0.05), but the Ob group had markedly higher weight, BMI, total cholesterol, triglycerides, and uric acid levels ( p < 0.001). Microbial analysis revealed reduced alpha diversity (Shannon index) in the Ob group and distinct microbial community structures among groups (PCoA, p < 0.001). LEfSe analysis showed enrichment of Escherichia-Shigella , Lactobacillus , and Parabacteroides in the Ob group, while Faecalibacterium , Enterobacter , and Agathobacter were predominant in the Nor group. The Ow group exhibited intermediate or specific enrichment, particularly in Ruminococcus gnavus group , Morganella , and Clostridium innocuum group . Correlation analysis indicated that bacteria abundant in the Nor group negatively correlated with BMI, TG, LDL-C, and positively with HDL-C, whereas those enriched in the Ow and Ob groups showed opposite trends. Four genera differentiated Ob from Ow individuals (AUC = 0.684), eight distinguished Ob from Nor (AUC = 0.787), and five separated Ow from Nor (AUC = 0.721). Integrating microbial and clinical data notably improved classification, with AUCs increasing to 0.908, 0.969, and 0.995, respectively. Conclusion: Intestinal microecological profiles vary significantly across BMI categories, and a model combining microbiota with metabolic markers shows strong potential for early obesity detection.
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (1) , e250026
Liver MRI–derived Proton Density Fat Fraction Predicts Diabetes Risk in Patients with Obesity: A Dose-Response Study
The liver MRI–derived proton density fat fraction (PDFF) independently predicted prediabetes and diabetes risk in patients with obesity, and the liver PDFF–dysglycemia relationship was partially mediated by liver enzymes.
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (1) , e250026
Liver MRI–derived Proton Density Fat Fraction Predicts Diabetes Risk in Patients with Obesity: A Dose-Response Study
The liver MRI–derived proton density fat fraction (PDFF) independently predicted prediabetes and diabetes risk in patients with obesity, and the liver PDFF–dysglycemia relationship was partially mediated by liver enzymes.
- 9 September 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (9) , 1669-1685
The X-Age Project to construct a Chinese aging clock
The global surge in the population of people 60 years and older, including that in China, challenges healthcare systems with rising age‐related diseases. To address this demographic change, the Aging Biomarker Consortium (ABC) has launched the X-Age Project to develop a comprehensive aging evaluation system tailored to the Chinese population. Our goal is to identify robust biomarkers and construct composite aging clocks that capture biological age, defined as an individual’s physiological and molecular state, across diverse Chinese cohorts. This Perspective outlines the core objectives, methodological framework and key deliverables of the X-Age Project, including cohort recruitment, standardized sample collection, multimodal data acquisition and clock model development. By integrating interdisciplinary expertise, we aim to provide a practical and scalable platform for understanding aging complexity and heterogeneity, early detection of accelerated aging and evaluation of aging interventions.
- 9 September 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (9) , 1669-1685
The X-Age Project to construct a Chinese aging clock
The global surge in the population of people 60 years and older, including that in China, challenges healthcare systems with rising age‐related diseases. To address this demographic change, the Aging Biomarker Consortium (ABC) has launched the X-Age Project to develop a comprehensive aging evaluation system tailored to the Chinese population. Our goal is to identify robust biomarkers and construct composite aging clocks that capture biological age, defined as an individual’s physiological and molecular state, across diverse Chinese cohorts. This Perspective outlines the core objectives, methodological framework and key deliverables of the X-Age Project, including cohort recruitment, standardized sample collection, multimodal data acquisition and clock model development. By integrating interdisciplinary expertise, we aim to provide a practical and scalable platform for understanding aging complexity and heterogeneity, early detection of accelerated aging and evaluation of aging interventions.
- Open Access
- 19 July 2025
- Published by Oxford University Press (OUP) in Life Medicine
- Vol. 4 (5)
A framework of biomarkers for adipose tissue aging: a consensus statement by the Aging Biomarker Consortium
Adipose tissue serves as a crucial energy storage and metabolic organ in the human body. With the surging of elderly population in China comes significant challenges in preventing and managing age-associated diseases, while adipose tissue aging represents one of the pivotal initiating events for multi-organ senescence. To address these challenges, the Aging China Biomarkers Consortium (ABC) has established an expert consensus on biomarkers of adipose tissue aging by digesting literature and collecting insights from scientists and clinicians. This consensus provides a comprehensive evaluation of the key changes and characteristics, as well as biomarkers related to adipose tissue aging and proposes a systematic framework categorizing these biomarkers into functional, structural and humoral dimensions. Within each dimension, the ABC recommends clinically and empirically validated biomarkers and parameters for assessing both physiological and pathological changes in adipose tissue during aging, which aims to establish a foundation for future prediction, diagnosis, early warning and treatment for adipose tissue aging and its related diseases, with the ultimate goal of improving adipose tissue health and promoting healthy aging in elderly populations both in China and worldwide.
- 19 July 2025
- Published by Oxford University Press (OUP) in Life Medicine
- Vol. 4 (5)
Open AccessA framework of biomarkers for adipose tissue aging: a consensus statement by the Aging Biomarker Consortium
Adipose tissue serves as a crucial energy storage and metabolic organ in the human body. With the surging of elderly population in China comes significant challenges in preventing and managing age-associated diseases, while adipose tissue aging represents one of the pivotal initiating events for multi-organ senescence. To address these challenges, the Aging China Biomarkers Consortium (ABC) has established an expert consensus on biomarkers of adipose tissue aging by digesting literature and collecting insights from scientists and clinicians. This consensus provides a comprehensive evaluation of the key changes and characteristics, as well as biomarkers related to adipose tissue aging and proposes a systematic framework categorizing these biomarkers into functional, structural and humoral dimensions. Within each dimension, the ABC recommends clinically and empirically validated biomarkers and parameters for assessing both physiological and pathological changes in adipose tissue during aging, which aims to establish a foundation for future prediction, diagnosis, early warning and treatment for adipose tissue aging and its related diseases, with the ultimate goal of improving adipose tissue health and promoting healthy aging in elderly populations both in China and worldwide.